“Unintended consequences” of diagnostics rules could lead to trials going abroad, group warns
Dozens of clinical trials have been delayed by an EU regulation on diagnostics, and hundreds more could also be pushed back, a group representing the pharmaceutical industry has claimed.
The In Vitro Diagnostic Regulation, which came into effect last year, sets rules on diagnostic tests done on blood or other samples taken from the human body.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.